Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04146857
Other study ID # NAPOXIA
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 30, 2019
Est. completion date December 30, 2020

Study information

Verified date July 2022
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sleeping under hypoxic conditions can impair cognition and autonomic nervous activity. A short daytime nap can modify these changes. Here we propose a randomized, cross-over study to evaluate the heart rate variability during a 90 min nap in a normobaric hypoxic chamber. In addition, we will investigate sleep architecture, vigilance, attention and memory.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date December 30, 2020
Est. primary completion date December 30, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 45 Years
Eligibility Inclusion Criteria: - Men and women - Age 25-45 years - BMI 20 - 28 kg/m^2 Exclusion Criteria: - Severe, manifest illnesses in need of treatment - Postoperative phases - Acute and chronic infections - Sleep disorders such as sleep apnea, insomnia or somnolence - Altitude exposure (> 2500 m asl) within 6 months before enrollment - Regular migraines - Smoking - Athletes - Significant weight change within 1 month before enrollment - Inability to understand significance and scope of the study - Drug or alcohol abuse

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Normoxia
Nap in hypoxia chamber at 20.9% oxygen (36 m asl)
Hypoxia 1
Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)
Hypoxia 2
Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)

Locations

Country Name City State
Germany Experimental & Clinical Research Center Berlin

Sponsors (1)

Lead Sponsor Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Riveros-Rivera A, Penzel T, Gunga HC, Opatz O, Paul F, Klug L, Boschmann M, Mähler A. Hypoxia Differentially Affects Healthy Men and Women During a Daytime Nap With a Dose-Response Relationship: a Randomized, Cross-Over Pilot Study. Front Physiol. 2022 Ma — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Heart rate variability Mean RR interval measured by polysomnography (ms) During 90 minutes nap under normoxic (20.9%) vs. 12.8% hypoxic condition
Secondary Heart rate variability Mean RR interval measured by polysomnography (ms) During 90 minutes nap under normoxic (20.9%) vs. 15.0% hypoxic condition
Secondary Sleep Efficiency (SE) Measured by continuous polysomnography (min) During 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Wake After Sleep Onset (WASO) Measured by continuous polysomnography (min) During 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Sleep Onset Latency (SOL) Measured by continuous polysomnography (min) During 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Low Frequency / High Frequency Band Mean LF/HF ratio measured by continuous ECG During 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Standard Deviation 1 / Standard Deviation 2 Mean SD1/SD2 ratio measured by continuous ECG During 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary RR intervals longer than 50 ms Percentage pNN50 measured by continuous ECG (%) During 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Core Body Temperature Mean temperature measured by continuous double sensor monitoring (°C) During 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Skin Temperature Mean temperature measured by continuous double sensor monitoring (°C) During 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Digit Span Task Longest memorized digit series (n, normal range 5-9, higher is better) After 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Psychomotor Vigilance Task Subscale 1 Number of lapses (normal range 0-6, higher is worse) After 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Psychomotor Vigilance Task Subscale 2 Mean reaction time (normal range 100-500 ms, higher is worse) After 90 min nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Color Stroope Task Subscale 1 Number of incongruency errors (normal range 0-5, higher is worse) After 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Color Stroope Task Subscale 2 Congruent response time (normal range 400-500 ms, higher is worse) After 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Color Stroope Task Subscale 3 Incongruent response time (normal range 600-800 ms, higher is worse) After 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Color Stroope Task Subscale 4 Congruent accuracy (above 95% is normal, higher is better) After 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
Secondary Color Stroope Task Subscale 5 Incongruent accuracy (above 85% is normal, higher is better) After 90 minutes nap under normoxic (20.9%) vs. two hypoxic conditions (12.8 and 15%)
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1

External Links